氟脲嘧啶药物敏感性与基因多态性研究进展(3)
[10]van Kuilenburg A B.Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil[J].Eur J Cancer，2004,40(7):939-950.
[11]Omura K.Clinical implication of dihydropyrimidine dehydrogenase activity in 5-FU based chemotherapy:mutations in the DPD gene，and DPD inhibitory fluoropyrimidines[J].Int J Clin Oncol，2003,8(3):132-138.
[12]Sato K，Kitajima Y，Miyoshi A，et al.Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells，and induces high sensitivity to 5-FU treatment[J].Int J Oncol，2006,29(2):429-435.
, 百拇医药
[13]Hasegawa S，Mukai M，Sato S，et al.Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination[J].Oncol Rep，2006,15(5):1185-1190.
[14]Kaori M，Takeshi S，Daisuke S，et al.Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines[J].J Gastroenterol，2006,41(2):140-150.
[15]Mizutani Y，Wada H，Fukushima M，et al.Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma[J].Cancer,2004,100(4):723-731.
, 百拇医药
[16]Kodera Y，Ito S，Fujiwara M，et al.Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer:correlation with drug sensitivity against 5-fluorouracil[J].Cancer Lett,2007,252(2):307-313.
[17]Kitajima M，Takita N，Hata M，et al.The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer[J].Oncol Rep,2006,15(1):161-165.
, 百拇医药
[18]Xiao J X，Sun H，Yang J，et al.Expression of thymidine phosphorylase in human colorectal carcinoma and its clinical significance[J].Ai Zheng，2004,23(3):303-305.
[19]Yasuno M，Mori T，Koike M，et al.Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma[J]，Oncol Rep，2005,13(3):405-412.
[20]Meropol N J，Gold P J，Diasio R B，et al.Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer[J].J Clin Oncol，2006,24(25):4069-4077.
, 百拇医药
[21]Jakobsen A，Nielsen J N，Gyldenkerne N，et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity[J].J Clin Oncol，2005,23(7):1365-1369.
[22]Etienne M C，Ilc K，Formento J L，et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms:relationships with 5-fluorouracil sensitivity[J].Br J Cancer，2004,90(2):526-534.
[23]Shrubsole M J，Shu X O，Ruan Z X，et al.MTHFR genotypes and breast cancer survival after surgery and chemotherapy:a report from the Shanghai Breast Cancer Study[J].Breast Cancer Res Treat，2005,91(1):73-79.
, http://www.100md.com
[24]Marcuello E，Altes A，Menoyo A，et al.Methylenetetrahydrofolate reductase gene polymorphisms:genomic predictors of clinical response to fluoropyrimidine-based chemotherapy[J].Cancer Chemother Pharmacol，2006,57(6):835-840.
[25]Sarbia M，Stahl M，von Weyhern C，et al.The prognostic significance of genetic polymorphisms(methylenetetrahydrofolate reductase C677T，methionine synthase A2756G，thymidilate synthase tandem repeat polymorphism)in multimodally treated oesophageal squamous cell carcinoma[J].British Journal of Cancer，2006,94:203-207.
[26]Ladner R D，Lynch F J，Groshen S,et al.dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues:association with survival and response to 5-Fluorouracil in colorectal cancer[J].cancer Research，2000,60:3493-3503.
[收稿日期]2007-10-24, http://www.100md.com(苏翔宇 李苏宜 刘 琳)
[11]Omura K.Clinical implication of dihydropyrimidine dehydrogenase activity in 5-FU based chemotherapy:mutations in the DPD gene，and DPD inhibitory fluoropyrimidines[J].Int J Clin Oncol，2003,8(3):132-138.
[12]Sato K，Kitajima Y，Miyoshi A，et al.Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells，and induces high sensitivity to 5-FU treatment[J].Int J Oncol，2006,29(2):429-435.
, 百拇医药
[13]Hasegawa S，Mukai M，Sato S，et al.Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination[J].Oncol Rep，2006,15(5):1185-1190.
[14]Kaori M，Takeshi S，Daisuke S，et al.Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines[J].J Gastroenterol，2006,41(2):140-150.
[15]Mizutani Y，Wada H，Fukushima M，et al.Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma[J].Cancer,2004,100(4):723-731.
, 百拇医药
[16]Kodera Y，Ito S，Fujiwara M，et al.Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer:correlation with drug sensitivity against 5-fluorouracil[J].Cancer Lett,2007,252(2):307-313.
[17]Kitajima M，Takita N，Hata M，et al.The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer[J].Oncol Rep,2006,15(1):161-165.
, 百拇医药
[18]Xiao J X，Sun H，Yang J，et al.Expression of thymidine phosphorylase in human colorectal carcinoma and its clinical significance[J].Ai Zheng，2004,23(3):303-305.
[19]Yasuno M，Mori T，Koike M，et al.Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma[J]，Oncol Rep，2005,13(3):405-412.
[20]Meropol N J，Gold P J，Diasio R B，et al.Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer[J].J Clin Oncol，2006,24(25):4069-4077.
, 百拇医药
[21]Jakobsen A，Nielsen J N，Gyldenkerne N，et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity[J].J Clin Oncol，2005,23(7):1365-1369.
[22]Etienne M C，Ilc K，Formento J L，et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms:relationships with 5-fluorouracil sensitivity[J].Br J Cancer，2004,90(2):526-534.
[23]Shrubsole M J，Shu X O，Ruan Z X，et al.MTHFR genotypes and breast cancer survival after surgery and chemotherapy:a report from the Shanghai Breast Cancer Study[J].Breast Cancer Res Treat，2005,91(1):73-79.
, http://www.100md.com
[24]Marcuello E，Altes A，Menoyo A，et al.Methylenetetrahydrofolate reductase gene polymorphisms:genomic predictors of clinical response to fluoropyrimidine-based chemotherapy[J].Cancer Chemother Pharmacol，2006,57(6):835-840.
[25]Sarbia M，Stahl M，von Weyhern C，et al.The prognostic significance of genetic polymorphisms(methylenetetrahydrofolate reductase C677T，methionine synthase A2756G，thymidilate synthase tandem repeat polymorphism)in multimodally treated oesophageal squamous cell carcinoma[J].British Journal of Cancer，2006,94:203-207.
[26]Ladner R D，Lynch F J，Groshen S,et al.dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues:association with survival and response to 5-Fluorouracil in colorectal cancer[J].cancer Research，2000,60:3493-3503.
[收稿日期]2007-10-24, http://www.100md.com(苏翔宇 李苏宜 刘 琳)